Daily Cardiology Research Analysis
Three high-impact cardiology studies stood out today: a Science Translational Medicine report identifies SLC38A2 as a novel endothelial amino acid transporter that modulates nitric oxide signaling and blood pressure in rodents; an European Heart Journal study links clonal hematopoiesis (especially TET2 mutations) to mortality in coronary artery disease and uncovers a macrophage LDLR-driven pro-atherogenic mechanism; and Mendelian randomization in European Heart Journal supports a causal relation
Summary
Three high-impact cardiology studies stood out today: a Science Translational Medicine report identifies SLC38A2 as a novel endothelial amino acid transporter that modulates nitric oxide signaling and blood pressure in rodents; an European Heart Journal study links clonal hematopoiesis (especially TET2 mutations) to mortality in coronary artery disease and uncovers a macrophage LDLR-driven pro-atherogenic mechanism; and Mendelian randomization in European Heart Journal supports a causal relationship between hypertensive disorders of pregnancy and later cardiovascular disease.
Research Themes
- Novel endothelial mechanisms and targets for hypertension
- Clonal hematopoiesis driving atherosclerosis and outcomes
- Women's cardiovascular health and pregnancy-related hypertension
Selected Articles
1. Inhibiting SLC38A2 lowers blood pressure in rodent models of hypertension.
This mechanistic study identifies the endothelial amino acid transporter SLC38A2 as a blood pressure regulator via nitric oxide signaling. Genetic manipulation of SLC38A2 in mice and endothelial cells and pharmacologic inhibition reduced blood pressure in hypertensive rodent models, highlighting a druggable pathway for hypertension.
Impact: Reveals a novel, druggable endothelial pathway for blood pressure control, potentially reshaping antihypertensive therapy development.
Clinical Implications: While preclinical, targeting SLC38A2 or its downstream NO signaling could yield first-in-class antihypertensives, especially for resistant hypertension. It also supports integrating endothelial amino acid transport into vascular health paradigms.
Key Findings
- SLC38A2 was identified as an endothelial regulator of blood pressure via nitric oxide signaling.
- Global and endothelial cell–specific perturbation of SLC38A2 in mice altered blood pressure.
- Pharmacologic inhibition of SLC38A2 lowered blood pressure in rodent hypertension models.
Methodological Strengths
- Use of both global and endothelial cell–specific genetic models to establish causality
- Convergent evidence across genetic and pharmacologic approaches in vivo
Limitations
- Preclinical animal work without human validation
- Incomplete safety, selectivity, and long-term efficacy data for SLC38A2 inhibitors
Future Directions: Validate SLC38A2 mechanisms in human endothelium and genetics, develop selective inhibitors, and test efficacy/safety in early-phase hypertension trials.
Hypertension remains a major global health burden with limited effective treatment options. In the present study, the sodium-dependent neutral amino acid transporter SLC38A2 was identified as a regulator of blood pressure (BP) through modulating endothelial nitric oxide (NO) signaling. Here, we show that mice with global and endothelial cell (EC)-specific
2. Clonal haematopoiesis of indeterminate potential and mortality in coronary artery disease.
In 8612 CAD patients, CHIP independently predicted higher 3-year mortality after propensity matching. Mechanistically, TET2 mutations localized to plaque macrophages, increased necrotic core and inflammation, and reprogrammed macrophages to upregulate LDLR and lipid uptake, linking epigenetic dysregulation to pro-atherogenic remodeling.
Impact: Bridges population-level risk with cellular mechanisms, identifying TET2-driven macrophage LDLR upregulation as a targetable pathway in high-risk CAD with CHIP.
Clinical Implications: CHIP genotyping may refine risk stratification in CAD and inform intensified lipid-lowering and anti-inflammatory strategies, particularly for TET2 mutation carriers.
Key Findings
- CHIP was associated with higher 3-year all-cause mortality in CAD after 1:1 propensity matching (HR 1.39, 95% CI 1.16-1.65).
- Multiple CHIP drivers (TET2, ASXL1, DNMT3A, JAK2, PPM1D, SF3B1, SRSF2, U2AF1) conferred increased mortality risk.
- TET2 mutations in plaque macrophages increased necrotic core, inflammation, and reduced stability; TET2+/- macrophages upregulated LDLR and lipid uptake via increased chromatin accessibility at the LDLR promoter.
Methodological Strengths
- Large angiographically confirmed CAD cohort with targeted deep sequencing and propensity score matching
- Integrated multi-omics across human plaques, transcriptomes, proteomics, and CRISPR-edited macrophages
Limitations
- Observational design susceptible to residual confounding despite matching
- Generalizability and clone size thresholds (VAF ≥2%) may influence risk estimates
Future Directions: Prospective interventional trials targeting inflammation or lipid uptake pathways in CHIP carriers; clinical utility of CHIP screening in CAD care pathways.
BACKGROUND AND AIMS: Clonal haematopoiesis of indeterminate potential (CHIP) has been associated with cardiovascular risk, but its prognostic relevance and mechanistic role in coronary artery disease (CAD) remains incompletely understood. This study investigated the association between CHIP and all-cause mortality in CAD and explored the cellular and molecular mechanisms, focusing on TET2 mutations. METHODS: Targeted deep sequencing of 13 CHIP driver genes in 8612 patients with angiographically confirmed CAD was performed. Clonal haematopoiesis of indeterminate potential carriers (variant allele frequency ≥2%) were propensity-score matched 1:1 to non-carriers. Mortality was assessed over 3 years. Mechanistic insights were derived from post-mortem high-sensitivity plaque proteomics (MISSION), RNA sequencing from carotid plaques (Athero-Express), monocyte-derived macrophage transcriptomes (STARNET), and CRISPR/Cas9-generated TET2+/- macrophages in vitro. RESULTS: Clonal haematopoiesis of indeterminate potential was associated with increased 3-year mortality (hazard ratio 1.39, 95% confidence interval 1.16-1.65, P < .001) in 2389 matched pairs. Mutations in TET2, ASXL1, DNMT3A, JAK2, PPM1D, SF3B1, SRSF2, and U2AF1 individually conferred higher mortality risk. In human plaques, CHIP mutations were found in lesional macrophages. TET2 CHIP carriers showed increased necrotic core size, inflammation, and reduced plaque stability. Multi-omics profiling revealed up-regulation of lipid metabolism and inflammatory pathways. TET2+/- macrophages exhibited increased LDLR expression and lipid uptake, linked to enhanced chromatin accessibility at the LDLR promoter. These findings were confirmed in carotid plaques, which showed increased LDLR and inflammasome-related gene expression in TET2 CHIP carriers. CONCLUSIONS: Clonal haematopoiesis of indeterminate potential is a predictor of mortality in CAD patients. TET2 mutations promote a pro-atherogenic macrophage phenotype via LDLR up-regulation and inflammatory activation, linking epigenetic dysregulation to adverse outcomes in CAD.
3. Preeclampsia, gestational hypertension, and cardiovascular disease risk: a genetic epidemiological study.
Two- and one-sample Mendelian randomization analyses show that genetic liability to preeclampsia and gestational hypertension causally increases risks of ischemic heart disease, myocardial infarction, stroke (including ischemic stroke), atrial fibrillation, and heart failure. Results were consistent across datasets and robust to pleiotropy.
Impact: Establishes likely causal links between hypertensive disorders of pregnancy and later cardiovascular disease, strengthening the evidence base for lifelong risk surveillance and early prevention in affected women.
Clinical Implications: Supports formal long-term cardiovascular screening and prevention pathways after hypertensive pregnancy disorders, including aggressive risk factor control and tailored follow-up in primary and cardiovascular care.
Key Findings
- Genetic predisposition to preeclampsia increased risks of IHD, MI, stroke (including ischemic stroke), AF, and HF in two-sample MR (e.g., MI OR 1.29, 95% CI 1.13–1.47).
- Genetic liability to gestational hypertension showed similar or higher risk elevations across outcomes (e.g., stroke OR 1.30, 95% CI 1.23–1.37).
- MR-Egger analyses did not suggest horizontal pleiotropy; one-sample MR in 202,876 UK Biobank women yielded consistent findings.
Methodological Strengths
- Two-sample MR using large GWAS instruments with multiple cardiovascular outcomes
- Replication via one-sample MR in UK Biobank and pleiotropy-robust sensitivity analyses
Limitations
- MR assumptions may be violated in unrecognized ways; findings pertain primarily to European ancestry populations
- Exposure definitions do not capture disease severity, timing, or recurrence across pregnancies
Future Directions: Define optimal postpartum surveillance and preventive strategies, assess risk modification via lifestyle and pharmacotherapy, and explore mechanistic pathways linking HDP to CVD.
BACKGROUND AND AIMS: Observational studies show that women with hypertensive disorders of pregnancy have greater risk of cardiovascular disease later in life. Whether these associations reflect causal pathways is uncertain. This study used genetic epidemiology to explore the causal relevance of preeclampsia and gestational hypertension on cardiovascular disease. METHODS: Two-sample Mendelian randomization (MR) analyses were conducted using summary-level data from FinnGen and from the to date largest consortia for each outcome. One-sample MR analyses were performed using individual-level data from 202 876 White British women from the UK Biobank. Genetic instruments for preeclampsia and gestational hypertension were from the most updated genome-wide association study (n = 20 064 preeclampsia cases; n = 703 117 controls; n = 11 027 gestational hypertension cases; n = 412 788 controls). RESULTS: In two-sample MR analyses, higher genetic predisposition to preeclampsia was associated with greater risk of ischaemic heart disease [odds ratio 1.20 (95% confidence interval 1.06-1.35)], myocardial infarction [1.29 (1.13-1.47)], stroke [1.23 (1.12-1.35)], ischaemic stroke [1.21 (1.10-1.33)], atrial fibrillation [1.13 (1.01-1.25)], and heart failure [1.11 (1.04-1.20)]. For higher genetic predisposition to gestational hypertension, corresponding odds ratios were 1.21 (1.10-1.33), 1.26 (1.16-1.36), 1.30 (1.23-1.37), 1.24 (1.17-1.32), 1.29 (1.17-1.42), and 1.09 (1.03-1.15). The MR-Egger results did not suggest pleiotropy. One-sample analyses were broadly consistent with the main findings. CONCLUSIONS: Genetic predisposition to hypertensive disorders of pregnancy was associated with greater risk of cardiovascular disease later in life, highlighting the importance of enhanced cardiovascular surveillance in this population.